Coya Therapeutics, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These programs are designed to address systemic inflammation and neuroinflammation across serious conditions such as neurodegenerative, autoimmune, chronic inflammatory, and metabolic diseases. Coya Therapeutics is particularly active in advancing treatments intended to restore immune balance and support disease-modifying approaches in areas with significant unmet medical need. Based in Houston, Texas, Coya Therapeutics operates within the broader healthcare and biotechnology markets, where its platform-based strategy positions it as a developer of specialized immunotherapy candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Arun Swaminathan Ph.D.
- Employees
- 8
- Headquarters
- Houston, TX, United States
- Website
- www.coyatherapeutics.com